TOP

Press Releases

You can read it in the journals and newspapers, or you can read it here first. Please check back frequently to see where the future is headed, compliments of Sequenom.

March 2014

Mar 21, 2014 SAN DIEGO, March 21, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced a resolution of litigation between the Company and Paul Hawran. Mr. Hawran served as the Company's Chief Financial Officer from April 2007 until September 2009. Mr. Hawran resigned in September 2009.  After September 2009, the Securities and Exchange Commission conducted an investigation concerning... Read more
Harry Hixson to Retire as Sequenom CEO Board Names William Welch as next CEO Dirk van den Boom Promoted to Chief Scientific and Strategy Officer Paul V. Maier to retire as CFO, Carolyn D. Beaver to assume role as CFO Mar 5, 2014           SAN DIEGO, March 5, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that Harry F. Hixson, Jr., Ph.D., will retire as Chief Executive Officer (... Read more
Mar 3, 2014 SAN DIEGO, March 3, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the 26th Annual Roth Conference at the Ritz Carlton in Dana Point, CA on March 9-12, 2014. William Welch, President and Chief Operating Officer, and Carolyn D. Beaver, Vice President and Chief Accounting Officer, will present on Tuesday, March 11, beginning at 12:00... Read more

February 2014

Record Quarterly and Annual Revenues; Annual Growth of 81% Over Prior Year Feb 27, 2014 SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative testing and genetic analysis solutions, today reported total revenues of $45.1 million for the fourth quarter and $162.4 million for the full year of 2013.  Net loss was $18.9 million, or $0.16 per share, for the fourth quarter and $107.4 million, or $0.93 per share, for the full year. ... Read more
Feb 13, 2014 SAN DIEGO, Feb. 13, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced it will report financial results for the fourth quarter and full year of 2013 after closing of the NASDAQ Global Market on Thursday, February 27, 2014. A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place on the same day at 5... Read more

January 2014

Jan 14, 2014 SAN DIEGO, Jan. 14, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative testing and genetic analysis solutions, announced today its wholly owned subsidiary, Sequenom Laboratories, entered into an agreement to offer access to its MaterniT21™ PLUS laboratory-developed test to Mayo Medical Laboratories. "We are delighted to expand our offerings to our national clients to offer the MaterniT21 PLUS test to physicians who have patients who... Read more

Pages